Skip to main content
100-mg daily dose of thalidomide in myeloma delays disease progression

A midstage Japanese study involving 34 patients with multiple myeloma, who were administered 100-mg maintenance doses of thalidomide daily, found that the dosage was safe and effective in hindering disease progression for longer than 36 months. The study's findings were reported in the International Journal of Hematology.

Full Story: